Ensocell

Ensocell is a Cambridge-based biotechnology company developing precision biologics for autoimmune, inflammatory, and fibrotic diseases.

Its platform integrates single-cell and spatial genomics with AI-based computational tools and advanced cell models to identify novel disease intervention points and design targeted therapeutics.

Founded by scientists from the Wellcome Sanger Institute, the company is based at Babraham Research Campus and has raised over $16 million from venture capital investors.